Valuation: Galapagos NV

Market Cap 1.55B 1.78B 1.44B 1.33B 2.5B 170B 2.54B 17.03B 6.67B 84.62B 6.69B 6.54B 279B P/E 2026 *
-11x
P/E 2027 * -8.31x
Enterprise Value -436M -502M -407M -374M -705M -47.82B -717M -4.8B -1.88B -23.85B -1.88B -1.84B -78.65B EV / Sales 2026 *
-30.6x
EV / Sales 2027 * -9.68x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 12/05/2025
Director of Finance/CFO 41 07/07/2025
Chief Operating Officer - 01/06/2026
Director TitleAgeSince
Director/Board Member 63 22/10/2019
Director/Board Member 49 07/10/2024
Director/Board Member 53 12/05/2025
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 1.78B
-0.36%+0.14%-2.06%+14.33% 48.22B
-2.71%-2.99%+398.09%+472.12% 38.79B
-0.71%+9.45%+27.90%+7.89% 38.41B
-0.71%-3.72%+4.94%+52.45% 34.88B
-2.41%+1.96%+11.68%+38.17% 29.19B
-0.66%-2.73%+35.50%+122.17% 16B
-0.19%-3.93% - - 16.05B
-0.62%+1.23%+2.76%+15.05% 13.53B
-3.15%-6.14%-4.82%-36.90% 12.22B
Average -1.15%-0.66%+59.25%+85.66% 27.48B
Weighted average by Cap. -1.23%+0.15%+75.56%+103.60%

Financials

2026 *2027 *
Net sales 14.24M 16.39M 13.3M 12.21M 23.01M 1.56B 23.41M 157M 61.4M 779M 61.55M 60.18M 2.57B 46.09M 53.03M 43.03M 39.5M 74.48M 5.05B 75.78M 507M 199M 2.52B 199M 195M 8.31B
Net income -811M -933M -757M -695M -1.31B -88.91B -1.33B -8.92B -3.5B -44.34B -3.5B -3.43B -146B -238M -274M -222M -204M -384M -26.08B -391M -2.62B -1.03B -13.01B -1.03B -1B -42.9B
Net Debt -1.98B -2.28B -1.85B -1.7B -3.21B -218B -3.26B -21.83B -8.55B -108B -8.57B -8.38B -358B -1.99B -2.29B -1.86B -1.71B -3.22B -219B -3.28B -21.95B -8.6B -109B -8.62B -8.43B -360B
Logo Galapagos NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B